LOGIN  |  REGISTER
Astria Therapeutics
C4 Therapeutics

A Clearer Vision of Surgery: Stryker Releases its Next-Generation of Advanced Surgical Cameras

September 14, 2023 | Last Trade: US$344.98 1.96 0.57
  • Stryker's 1788 camera platform brings enhanced technology to the operating room – including a wider color gamut, more vivid white light and new fluorescence imaging capabilities

SAN JOSE, California, USA, Sept. 14, 2023 /PRNewswire/ -- Stryker (NYSE: SYK), one of the world's leading medical technology companies, today unveiled the next-generation of minimally invasive surgical cameras: the 1788 platform. The fully enhanced camera is set to advance surgery across multiple specialties.

The all-in-one surgical camera platform offers a more vibrant image with balanced lighting, a wider color gamut and clearer delineation of fluorescence signals1. The platform is designed for improved visualization of blood flow and critical anatomy and has the ability to visualize multiple optical imaging agents – when it matters most.

"When it comes to surgical outcomes, dependable imaging is one of the most critical factors. With the enhanced imaging capabilities of the 1788, surgeons have a complete surgical camera technology that provides consistent and vivid imaging," said Dr. Matthew Albert, colon and rectal surgeon at Advent Health. "Patients deserve high-quality care, and we're thrilled that this solution allows our operating room teams to deliver just that."

The 1788 platform is compatible with the currently marketed imaging agents and adaptable to new agents and fluorescence modes as they become available.

The advances in this technology also enable a broader range of clinical applications and enhance additional specialties, including urology, neurology, and ear, nose and throat.

"Stryker partnered with our surgeon users to design the 1788 platform to be a powerful partner in the OR and to enhance the surgical experience across specialties. This is another way in which Stryker is living up to its rich legacy of delivering the most innovative surgical technology to help surgeons support improved patient outcomes," said Andrés Rosales, vice president and general manager of Stryker's Endoscopy business unit.

"The early feedback has been that the 1788 camera delivers better fluorescence imaging and an enhanced user experience, which is particularly helpful in those deep or highly complex cases when surgeons are working in tight cavities—such as sinus cases and pituitary resections," added Rosales.

"Clear visualization is a necessity when a patient's life is in your hands. It's important that surgeons can visualize perfusion and critical anatomy to make surgical decisions intraoperatively," said Dr. Albert.

Notable features of the 1788 platform include:

  • Wider color gamut for 62.5x more visible colors
  • Improved fluorescence imaging with better consistency
  • High dynamic range and new tone mode for more balanced lighting
  • Cleared to visualize CYTALUX®, an imaging agent designed to illuminate lung and ovarian cancer intraoperatively2

Stryker will debut this new technology at the American College of Surgeons' Clinical Congress on October 23-25, 2023, in Boston at Booth #620.

Learn more at www.stryker.com

About Stryker

Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at stryker.com.

Media contacts

Erin Noel, Inprela
651.677.2027 ext. 1027 
This email address is being protected from spambots. You need JavaScript enabled to view it.

 Laura Vickers, Stryker
214.926.3673
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

1 1000904469 Comparisons are to previous generation unless noted otherwise
2 NDA 214907 for approved indications of use
Disclaimer: Dr. Albert is a paid consultant for Stryker

 

 

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB